RxDoctor Payments Data

Kabir Das, MD

Internal Medicine · Stockbridge, GANPI 1699955377

Payments from drug & device makers

$2,749in general payments, 2019–2025

Across 173 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$512
  • Pfizer$386
  • Novo Nordisk$270
  • Amgen$240
  • AstraZeneca$227
  • Johnson & Johnson$128
  • plus $986 from 20 others

What the payments were for

  • Food & beverage$2,62095%
  • Education$1295%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,749 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$89,236
Medicare patients
206
Services billed
2,999

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide171$210,478
EliquisApixaban144$132,862
JardianceEmpagliflozin67$75,335
FarxigaDapagliflozin Propanediol60$65,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$62,263
TrulicityDulaglutide38$52,515
MounjaroTirzepatide48$51,526
JanuviaSitagliptin Phosphate54$50,226
MyrbetriqMirabegron48$33,764
LinzessLinaclotide41$30,688
TradjentaLinagliptin20$20,956
ProliaDenosumab12$20,817
EntrestoSacubitril/Valsartan18$19,926
JanumetSitagliptin Phos/Metformin Hcl14$16,692
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$270$210,478171 claims
PfizerEliquis$386$132,862144 claims
Lilly USA, LLCTrulicity, Mounjaro$105$104,04186 claims
Boehringer IngelheimJardiance, Tradjenta$91$96,29187 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$227$91,878130 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$63$80,609116 claims
MerckJanuvia, Janumet$43$66,91768 claims
Astellas Pharma US IncMyrbetriq$512$33,76448 claims
AbbVieLinzess$97$30,68841 claims
AmgenProlia$240$20,81712 claims
NovartisEntresto$12$19,92618 claims
Johnson & JohnsonInvokana$128$7,23312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →